Dogwood Therapeutics, Inc.
NASDAQ:DWTXBiotechnology
Healthcare
$1.52 +2.22%
+$0.04 today
- Market cap
- $51.12M
- Beta
- 1.76
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.84
52W Low $1.28High $9.50
Volume 0.12M
Average 0.09M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$27.97M
FY 2025 · Annual
Net Income
-$34.26M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.8M | 8.07M | 1.73M | 3.53M | 21.87M |
| Selling, General & Admin | 4.85M | 4.25M | 3.72M | 8.7M | 6.1M |
| Operating Expenses | 15.64M | 12.32M | 5.45M | 12.23M | 27.97M |
| Depreciation & Amortization | 0 | 0 | 0 | 12.18K | 2.06K |
| EBITDA | (15.96M) | (12.25M) | (5.3M) | (12.25M) | (34.03M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.64M) | (12.32M) | (5.45M) | (12.23M) | (27.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5.67K | 67.48K | 150.9K | 0 | 96.94K |
| Interest Expense | 0 | 0 | 0 | 92.19K | 0 |
| Other Income / Expenses | (319.33K) | 67.48K | 150.9K | (122.98K) | (6.07M) |
| Income Before Tax | (15.96M) | (12.25M) | (5.3M) | (12.35M) | (34.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | (503) | 221.1K |
| Net Income | (15.96M) | (12.25M) | (5.3M) | (12.35M) | (34.26M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (47.90) | (27.66) | (7.05) | (12.52) | (4.32) |
| EPS (Diluted) | (47.90) | (27.66) | (7.05) | (12.52) | (4.32) |
| 333.17K | 442.8K | 751.07K | 1.03M | 8.22M | |
| 333.17K | 442.8K | 751.07K | 1.03M | 8.22M |
DWTX Earnings Waterfall · TTM
NASDAQ:DWTX · Revenue to Net Income
Key Ratios
EPS$-10.60
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$28.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-10.60, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 7, 2025 | |
| 8-K | Current report | Nov 6, 2025 | |
| DEF 14A | DEF 14A filing | Oct 20, 2025 | |
| S-3/A | S-3/A filing | Oct 16, 2025 | |
| DEFA14A | DEFA14A filing | Oct 9, 2025 |
How much revenue does DWTX generate?
Dogwood Therapeutics, Inc. (DWTX) reported $0.00 of revenue in fiscal 2025.
Is DWTX profitable?
Dogwood Therapeutics, Inc. (DWTX) reported -$34.26M of net income.
Continue the stock analysis
Jump to another research area for this company.